Two of its biggest sellers — Eliquis and cancer immunotherapy Opdivo — will lose patent exclusivity in the coming years. Cancer blockbuster Revlimid has been suffering from generic competition ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...